Display options
Cite
Churg A, Le Stang N, Dacic S, et al. Solid papillary mesothelial tumor. Mod Pathol. 2021;doi: 10.1038/s41379-021-00899-3.
Churg, A., Le Stang, N., Dacic, S., Pissaloux, D., Begueret, H., Dartigues, P., Giusiano-Courcambeck, S., Sequeiros, R., Pairon, J. C., Tirode, F., & Galateau-Sallé, F. (2021). Solid papillary mesothelial tumor. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, . https://doi.org/10.1038/s41379-021-00899-3
Churg, Andrew, et al. "Solid papillary mesothelial tumor." Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc vol. (2021). doi: https://doi.org/10.1038/s41379-021-00899-3
Churg A, Le Stang N, Dacic S, Pissaloux D, Begueret H, Dartigues P, Giusiano-Courcambeck S, Sequeiros R, Pairon JC, Tirode F, Galateau-Sallé F. Solid papillary mesothelial tumor. Mod Pathol. 2021 Sep 03; doi: 10.1038/s41379-021-00899-3. Epub 2021 Sep 03. PMID: 34480081.
Copy Download .nbib Format: NLM
Share it on

Mod Pathol. 2021 Sep 03; doi: 10.1038/s41379-021-00899-3. Epub 2021 Sep 03.

Solid papillary mesothelial tumor.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Andrew Churg, Nolwenn Le Stang, Sanja Dacic, Daniel Pissaloux, Hugues Begueret, Peggy Dartigues, Sophie Giusiano-Courcambeck, Ruth Sequeiros, Jean-Claude Pairon, Franck Tirode, Francoise Galateau-Sallé

Affiliations

  1. Department of Pathology, Vancouver General Hospital and University of British Columbia, Vancouver, BC, Canada. [email protected].
  2. Department of BioPathology Centre Léon Bérard, MESOPATH College, MESONAT, MESOBANK, Lyon, France.
  3. Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  4. Department of Biopathology, Unit of Molecular Pathology and Cancer Research Center of Lyon, INSERM, Lyon, France.
  5. Team Genetics, Epigenetics and Biology of Sarcomas, Univ Lyon, Université Claude Bernard Lyon 1, INSERM, Cancer Research Center of Lyon, Centre Léon Bérard, Lyon, France.
  6. Faculté de médecine and CHI Creteil, Service de Pathologies professionnelles et de l'Environnement, IST-PE, INSERM, UPEC, Creteil, France.

PMID: 34480081 DOI: 10.1038/s41379-021-00899-3

Abstract

We report nine examples of a previously undescribed type of peritoneal circumscribed nodular mesothelial tumor characterized by nests or sheets of mesothelial cells with sharp cell borders and extremely bland, sometimes grooved, nuclei. In some cases, nests were separated by fibrous bands. All patients were women, age range 30-72 years (median 52 years). All tumors were incidental findings during surgery and grossly were either solitary nodules or a few small nodules on the peritoneal surface. Referring pathologic diagnoses included diffuse malignant mesothelioma, localized malignant mesothelioma, well-differentiated papillary mesothelioma, and adenomatoid tumor. No tumor showed BAP1 loss by immunohistochemistry nor deletion of CDKN2A by FISH. RNA-seq revealed that these tumors clustered together and were distinct from peritoneal diffuse malignant mesotheliomas. Very few mutations or translocations were found, none of them recurrent from tumor to tumor, and no tumor showed an abnormality in any of the genes typically mutated/deleted in diffuse malignant mesothelioma. Array CGH on three cases revealed two with a completely flat profile and one with a small deletion at 3q26-3q28. On follow-up (range 5-60, median 34 months), there were no deaths, no recurrences, and no evidence of metastatic disease nor local spread; one case that initially had scattered nodules on the pelvic peritoneum had the same pattern of nodules at a second look operation 2 years later. We propose the name solid papillary mesothelial tumor for these lesions. These appear to be either benign or very low-grade tumors that need to be separated from malignant mesotheliomas.

© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.

References

  1. WHO Classification of Tumours Editorial Board. Thoracic Tumours. WHO Classification of Tumours Series 5th edn, Vol. 5, https://publications.iarc.fr/595 (International Agency for Research on Cancer, 2021). - PubMed
  2. Wadowski, B., De Rienzo, A. & Bueno, R. The molecular basis of malignant pleural mesothelioma. Thorac Surg. Clin. 30, 383–393 (2020). - PubMed
  3. Wang, L. M. et al. Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis. Oncotarget 8, 68863–68872 (2017). - PubMed
  4. Leblay, N. et al. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J. Thorac. Oncol. 12, 724–733 (2017). - PubMed
  5. Singhi, A. D. et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod. Pathol. 29, 14–24 (2016). - PubMed
  6. Shrestha, R. et al. Well-Differentiated papillary mesothelioma of the peritoneum is genetically distinct from malignant mesothelioma. Cancers (Basel) 12, 1568 (2020). - PubMed
  7. Stevers, M. et al. Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42. Mod. Pathol. 32, 88–99 (2019). - PubMed
  8. Goode, B. et al. Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation. Mod. Pathol. 31, 660–673 (2018). - PubMed
  9. Itami, H. et al. TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma. Hum. Pathol. 111, 59–66 (2021). - PubMed
  10. Galateau-Salle, F. et al. Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center. J. Thorac. Oncol. 15, 1037–1053 (2020). - PubMed
  11. Marchevsky, A. M. et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod. Pathol. 33, 281–296 (2020). - PubMed
  12. Hung, Y. P. et al. Molecular characterization of localized pleural mesothelioma. Mod. Pathol. 33, 271–280 (2020). - PubMed

Publication Types